MedTrace Logo

Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216

NCT00161941 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 321

Last updated 2015-05-21

No results posted yet for this study

Summary

The primary aim of the study is to show that the antibody response to hepatitis B, acellular pertussis toxin and inactivated poliovirus antigens after the 4th vaccination with Hexavac® is not influenced by the concomitant administration of NeisVac-C.

Conditions

  • Meningococcal Meninigitis, Serogroup C

Sponsors & Collaborators

Principal Investigators

  • Ulrich Behre, MD · Private practice, Hauptstrasse, Kehl, Germany

Eligibility

Min Age
5 Months
Max Age
22 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-06-30
Completion
2003-12-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00161941 on ClinicalTrials.gov